

## Cell Therapy Product Proposal

### Instructions

Please complete the sections below to request access to ACTL cGMP systems and facilities. Submit completed form and attachments to [actl@ucsd.edu](mailto:actl@ucsd.edu).

Date Prepared

### 1. Client Information

<b>Organization Name</b>			
<b>Organization Address</b>			
<b>Client Name</b>			
<b>Client Phone</b>			
<b>Client Email</b>			
<b>Additional project-related contacts</b>			
<b>Name</b>	<b>Title</b>	<b>Phone</b>	<b>Email</b>

### 2. Service Requested

Choose the services requested for this project (check all that apply):

Service 1: Consultation

Service 2: Process Development

Service 3: Manufacturing

Service 4: Storage

### 3. Project/Clinical Protocol Information

Briefly describe the rationale for use, the therapeutic goal and clinical impact of your cell therapy product.

**4. Regulatory Status**

Provide the regulatory status of the project (check all that apply):

IND/Health Authority (HA) submission filed

Pre-IND Meeting completed

IRB Review completed

Other (please describe below)

Provide description of communication with FDA/HA or other regulatory approval status if applicable.

**5. Cell Therapy Product Information**

**A. Cell Therapy Name and Description**

Briefly describe the cell therapy product, the cell source/starting material and culture methods to be used for production.

**B. Raw Materials**

Provide a list of critical components including their source and qualification status, if known.

**C. Cell Therapy Manufacturing Process**

Briefly describe proposed plan of GMP manufacturing and characterization for the cell therapy product, including scale/format of the process and duration of production campaign. Please also provide a list of anticipated in-process/intermediate analytical tests to be performed and product specifications. Attach a process flow diagram if available.

**D. Facilities/Equipment Needs**

Mention any special facilities/equipment requirements for this project.

## 6. Clinical Service Information

Mention where patients will be treated (UCSD and/or elsewhere). What hospital and/or clinical services are likely to be involved?

## 7. Timeline

Expected start of GMP cell production	
Start Date of Clinical Trial	
Duration of Clinical Trial	
Anticipated Number of Patients to be enrolled	

## 8. Funding Information

What is the status of funding (check one):

Budget is complete and funded

Budget is estimated and under review

Budget is in development

List funding source/s (e.g. NIH, CIRM, Foundations, Industry or Corporate Sponsor)

## 9. Publications

Provide a list of references and attach pdf of prior publications.

For questions and/or additional information please contact **Holly Young** (Facility Director; [hyyoung@ucsd.edu](mailto:hyyoung@ucsd.edu)) or **Dr. Dan Kaufman** (Scientific/Medical Director; [dskaufman@ucsd.edu](mailto:dskaufman@ucsd.edu)).